Simulect Versus ATG in Sensitized Renal Transplant Patient
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Induction therapy by either T-cell depleting polyclonal antibodies such as anti-thymocyte
globulins (ATG) or non-depleting anti-interleukine 2 receptor monoclonal antibodies
(anti-CD25 moAb: basiliximab or daclizumab) are used to prevent acute rejection, especially
in highly sensitized patients. Both induction therapy regimens have a different tolerance
profile. Infections and haematological side-effects are more frequently reported in patients
receiving ATG.
The aim of the pilot study is to evaluate ATG and basiliximab induction therapy in de novo
sensitized kidney-transplant patients (incompatible grafts rate ≥ 50%) without donor specific
antibodies (DSAs) detected by Luminex.